Merck (MRK) Non Operating Income (2009 - 2026)
Merck (MRK) reported Non Operating Income of -$138.0 million for Q1 2026, down 494.29% year-over-year from $35.0 million in Q1 2025, and up 68.06% quarter-over-quarter from -$432.0 million in Q4 2025.
Merck (MRK) Non Operating Income (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Non Operating Income data on file, last reported at -$138.0 million in Q1 2026.
- Non Operating Income for Q1 2026 came in at -$138.0 million, down 494.29% year-over-year; the trailing twelve-month figure through Mar 2026 was -$325.0 million (down 1260.71% YoY), and the FY2025 annual result was -$151.0 million, down 729.17% from the prior year.
- Non Operating Income rose to -$138.0 million in Q1 2026 per MRK's latest filing, from -$432.0 million in the prior quarter.
- Over five years, Non Operating Income peaked at $238.0 million in Q3 2025 and troughed at -$708.0 million in Q1 2022.
- A 5-year average of -$131.1 million and a median of -$89.0 million in 2023 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2022 and 2024: Non Operating Income sank 525.24% in 2022, then jumped 228.57% in 2024.
- A 5-year view of Non Operating Income shows it stood at $75.0 million in 2022, then sank by 204.0% to -$78.0 million in 2023, then slumped by 62.82% to -$127.0 million in 2024, then slumped by 240.16% to -$432.0 million in 2025, then soared by 68.06% to -$138.0 million in 2026.
- Business Quant data shows MRK's Non Operating Income at -$138.0 million in Q1 2026, -$432.0 million in Q4 2025, and $238.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | 195.49 Mn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | -65.00 Mn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | -294.00 Mn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | -2.31 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | -32.00 Mn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -138.00 Mn |
| Dec 31, 2025 | -432.00 Mn |
| Sep 30, 2025 | 238.00 Mn |
| Jun 30, 2025 | 7.00 Mn |
| Mar 31, 2025 | 35.00 Mn |
| Dec 31, 2024 | -127.00 Mn |
| Sep 30, 2024 | 162.00 Mn |
| Jun 30, 2024 | -42.00 Mn |
| Mar 31, 2024 | 33.00 Mn |
| Dec 31, 2023 | -78.00 Mn |
| Sep 30, 2023 | -126.00 Mn |
| Jun 30, 2023 | -172.00 Mn |
| Mar 31, 2023 | -89.00 Mn |
| Dec 31, 2022 | 75.00 Mn |
| Sep 30, 2022 | -429.00 Mn |
| Jun 30, 2022 | -438.00 Mn |
| Mar 31, 2022 | -708.00 Mn |
| Dec 31, 2021 | 334.00 Mn |
| Sep 30, 2021 | 450.00 Mn |
| Jun 30, 2021 | 103.00 Mn |